Incidence of lung cancer among patients with tuberculosis: a nationwide cohort study in Lithuania von Everatt, R., Kuzmickiene, I., Davidaviciene, E., Cicenas, S.

Volltext

Smoking, hormonal factors and molecular markers in female lung cancer von Schveigert, D, Krasauskas, A, Didziapetriene, J, Kalibatiene, D, Cicenas, S

Volltext

88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE PHASE III TITAN STUDY von Ciuleanu, T, Stelmakh, L, Cicenas, S, Gonzalez, E. Esteban

Volltext

The value of MMP-9 for breast and non-small cell lung cancer patients' survival von Schveigert, D, Cicenas, S, Bruzas, S, Samalavicius, NE, Gudleviciene, Z, Didziapetriene, J

Volltext

Lithuania hosts International Conference on Lung Cancer Vilnius Lithuania, 22–24 May 2003 von Cicenas, S

Volltext

Outcome and treatment strategy in female lung cancer: a single institution experience von Cicėnas, S, Kurtinaitis, J, Smailytė, G

Volltext

1350P Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC von Paulus, A., Zemaitis, M., Cicenas, S., Zvirbule, Z., Rydberg-Millrud, C., Magnusson, S., Losic, N., Tersago, D., Paz-Ares, L.G.

Volltext

P02.24 Liquid Biopsy Mutation Profiling in Non-Small Cell Lung Cancer von Gedvilaitė, V., Šeštokaitė, A., Sabaliauskaite, R., Jarmalaite, S., Cicenas, S.

Volltext

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study) von Eide, Inger Johanne Zwicky, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Brustugun, Odd Terje

Volltext

9096 POSTER EGFR-targeting Chimeric Monoclonal lgG-1 Antibody Cetuximab in a Phase ll/lll Study Added Either to Gemcitabine Followed by Docetaxel or Carboplatin Plus Gemcitabine fo... von Kortsik, C, Schmid-Bindert, G, Pilz, L.R, Cicenas, S, Eschbach, C, Kollmeier, J, Schumann, C, Serke, M, Steins, M, Manegold, C

Volltext

Occupational characteristics of respiratory cancer patients exposed to asbestos in Lithuania von Everatt, R Petrauskaitė, Smolianskieṅ, G, Tossavainen, A, Cicėnas, S, Jankauskas, R

Volltext

P1.15-09 Trends in Lung Cancer Survival in Lithuania von Gedvilaite, V., Danila, E., Cicenas, S., Smailyte, G.

Volltext

538P Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung ca... von Awada, A.H., Zematis, M., Ochsenreither, S., Eefsen, R.L., Arnold, D., Cicenas, S., Yachnin, J., Pfeiffer, P., Paz-Ares, L., Jungels, C., Greil, R., Poulsen, L. Østergaard, Van Cutsem, E., Ribas, I. Garcia, Thorsson, L., Collignon, J.J.

Volltext

Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study von Eide, Inger Johanne Zwicky, Grut, Harald, Helland, Åslaug, Ekman, Simon, Sørensen, Jens Benn, Hansen, Karin Holmskov, Grønberg, Bjørn Henning, Cicenas, Saulius, Koivunen, Jussi Pekka, Mellemgaard, Anders, Brustugun, Odd Terje

Volltext

DNA repair gene expression in bronchial washing fluid as new molecular tool for clinical outcome decision von Schveigert, D., Askinis, R., Fadejeva, J., Sapoka, V., Krasauskas, A., Cicenas, S.

Volltext

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials von Eide, Inger Johanne Zwicky, Stensgaard, Simone, Helland, Åslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, Grønberg, Bjørn Henning, Sørensen, Boe Sandahl, Brustugun, Odd Terje

Volltext

P59.15 Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)? von Eide, I.J., Dyrbekk, A.P., Helland, Å., Ekman, S., Koivunen, J., Cicenas, S., Grønberg, B., Bisha, I., Haberichter, T., Lakis, S., Chan, J., Lewis, A., Martin, P., Cooper, Z., Brustugun, O.T.

Volltext

P2.03-037 Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study von Eide, I.J., Helland, Å., Borrisova, S., Ekman, S., Cicenas, S., Koivunen, J., Grønberg, B.H., Brustugun, O.T.

Volltext

P2.03-035 Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study von Eide, I.J., Helland, Å., Borrisova, S., Ekman, S., Cicenas, S., Koivunen, J., Grønberg, B.H., Brustugun, O.T.

Volltext

P17.02 Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients – a Phase II Translational and Biomarker Study von Haakensen, V.D., Horndalsveen, H., Nymoen, H.M., Holgersson, G., Land, L. Holm, Koivunen, J., Cicenas, S., Oselin, K., Madebo, T., Van Helvoirt, R., Helbekkmo, N., Grønberg, B.H., Aanerud, M., Rogg, L., Helland, Å.

Volltext